Commercial Supply Agreement

OXB announced a new Commercial Supply Agreement with Bristol Myers Squibb (BMS) to manufacture and supply lentiviral vectors for BMS’ CAR‑T programmes. The partnership, originally established in 2020, will shift to commercial production in 2026, pending regulatory approval. The multi‑year deal is projected to generate significant revenue, reinforcing OXB’s medium‑term financial guidance. OXB highlighted its 30‑year expertise in viral‑vector development and its focus on cell and gene‑therapy CDMO services, underscoring its role in supporting the commercial success of CAR‑T programmes. The agreement marks a key milestone for both companies, as noted by OXB’s Chief Business Officer and BMS Vice President, signifying the transition from clinical to commercial manufacturing.